



ASX/media release

26 July 2007

FY2007 contracted revenue increases 86% to \$6.3 m

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures non-invasively, announces record sales for FY2007. New business closed in FY2007 of \$6.3 million is an 86 per cent increase over FY2006 (\$3.4 million) and comprises \$4.8 million (unaudited) in recognised revenue for FY2007 and a further \$1.5 million which will be recognised in future periods.

In the United States, contracted revenue increased over 200 per cent from 2006 levels on a constant currency basis (USD). FY2007 recognized sales in USA increased by 66 per cent in the year compared to FY2006, on a constant currency basis (USD). In Europe, new distribution agreements and expanded contracts with existing distributors helped FY2007 sales grow by 77 per cent on a constant currency basis (Euro). The Rest of World (ROW) market, which includes Australia and New Zealand, turned the corner in the second half, growing 32 per cent compared to the second half of 2006.

AtCor chief executive officer, Duncan Ross, said that the company's performance was positive and in line with its expectations. "AtCor is well positioned for a strong start in 2008 in all markets. I am particularly encouraged by the response the company is receiving from the pharmaceutical sector, which is now recognizing the importance of including central blood pressure monitoring in clinical trials. Major studies have shown that the impact their compounds can have on the cardiovascular system is not evident when measured using the traditional cuff blood pressure alone. Further impressive growth is anticipated through the next financial year."

Full year results will be announced on 23 August 2007.

About AtCor

AtCor Medical develops and markets products for the early detection and management of cardiovascular disease. More than 1,000 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. AtCor has operations in Australia, the United States, and Europe. AtCor is listed on the ASX under code ACG. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au